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Abstract
The implementation of expanded newborn screening programs reduced mortality and morbidity in medium-chain acyl-CoA
dehydrogenase deficiency (MCADD) caused by mutations in the ACADM gene. However, the disease is still potentially fatal.
Missense induced MCADD is a protein misfolding disease with a molecular loss-of-function phenotype. Here we established
a comprehensive experimental setup to analyze the structural consequences of eight ACADM missense mutations
(p.Ala52Val, p.Tyr67His, p.Tyr158His, p.Arg206Cys, p.Asp266Gly, p.Lys329Glu, p.Arg334Lys, p.Arg413Ser) identified after
newborn screening and linked the corresponding protein misfolding phenotype to the site of side-chain replacement with
respect to the domain. With fever being the crucial risk factor for metabolic decompensation of patients with MCADD,
special emphasis was put on the analysis of structural and functional derangements related to thermal stress. Based on
protein conformation, thermal stability and kinetic stability, the molecular phenotype in MCADD depends on the structural
region that is affected by missense-induced conformational changes with the central b-domain being particularly prone to
structural derangement and destabilization. Since systematic classification of conformational derangements induced by
ACADM mutations may be a helpful tool in assessing the clinical risk of patients, we scored the misfolding phenotype of the
variants in comparison to p.Lys329Glu (K304E), the classical severe mutation, and p.Tyr67His (Y42H), discussed to be mild.
Experiments assessing the impact of thermal stress revealed that mutations in the ACADM gene lower the temperature
threshold at which MCAD loss-of-function occurs. Consequently, increased temperature as it occurs during intercurrent
infections, significantly increases the risk of further conformational derangement and loss of function of the MCAD enzyme
explaining the life-threatening clinical courses observed during fever episodes. Early and aggressive antipyretic treatment
thus may be life-saving in patients suffering from MCADD.
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There is no other relevant declaration relating to employment, consultancy, patents, products in development or marketed products. This does not alter the
authors’ adherence to all the PLOS ONE policies on sharing data and materials.
* E-mail: Ania.Muntau@med.lmu.de
. These authors contributed equally to this work.
" These authors also contributed equally to this work.
¤a Current address: Department of Pediatrics, University Hospital, Salzburg, Austria
¤b Current address: LEUKOCARE AG, Munich, Germany
¤c Current address: Munich Leukemia Laboratory, Munich, Germany
Introduction
Medium-chain acyl-CoA dehydrogenase deficiency (MCADD;
MIM #201450) is the most common fatty acid disorder arising
from mutations in the ACADM gene (MIM #607008). In the
absence of catabolic stress individuals with MCADD are mostly
asymptomatic, but intercurrent illness or prolonged fasting may
lead to episodes of coma with hypoketotic hypoglycemia and
hepatic dysfunction [1,2]. In the absence of newborn screening
(NBS) for MCADD, premature death or serious disability occurs
in 20% to 25% of children with the disorder [3]. If MCADD is
identified by NBS, families are instructed to avoid prolonged
fasting and to have their children hospitalized for glucose infusion
during acute illness. These measures reduce the frequency of
sudden death in MCADD, but unfortunately, some patients die in
spite of early diagnosis and implementation of emergency
procedures [4]. Still occurring fatal courses may be due to the
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incomplete understanding of the underlying molecular phenotype
linked to the mutations found in these patients.
Eighty percent of symptomatic patients diagnosed before the
establishment of expanded NBS programs in Europe and in the
US are homozygous for the mutation p.Lys329Glu (c.985A.G),
18% carry this allelic variant in the heterozygous state [5,6] with
an allele frequency of 90% in this group. Thus, this mutation is
tightly linked to the risk of clinical disease manifestation. MCADD
patients identified by expanded NBS show a considerably wider
genetic heterogeneity with the p.Lys329Glu mutation present only
on 47% to 63% of defective alleles [3,7–10]. p.Tyr67His
(c.199C.T) is the second most prevalent mutation identified in
newborns with MCADD and is discussed to be less severe [7,9–
12]. In addition, numerous novel mutations have been identified
in the NBS cohort, leading to the current number of 81 different
ACADM mutations with 80% of these being missense or small
insertions/deletions (www.hgmd.org). The clinical relevance of the
majority of these mutations is so far unknown. Notably, novel
genotypes identified in NBS are associated with risk of sudden
death [4]. Clinical observation may support the hypothesis that the
two most common mutations in the ACADM gene causing the
amino acid substitutions p.Lys329Glu, the predominant variant in
symptomatic patients, and p.Tyr67His, a biochemically mild
variant solely found in presymptomatic infants in NBS, form the
two ends of a phenotypic spectrum in MCADD.
Experimental evidence led to the current view that missense
induced MCADD is a protein misfolding disease with a loss-of-
function molecular phenotype [13–16]. In spite of differences in
severity both p.Lys329Glu and p.Tyr67His caused protein
misfolding [16,17]. In a previous study, we provided first
experimental evidence for the impact of eight additional ACADM
mutations identified in NBS on MCAD structure and function and
all of these were clearly associated with conformational derange-
ment and decreased protein stability [16]. High rates of
aggregation and degradation upon recombinant expression
indicated a severe protein misfolding molecular phenotype for
two further mutations from Bavarian NBS, namely p.Asp223Gly
and p.Ile331Thr, and precluded these variants from further
experimental exploration [16].
The analysis of the structural consequences of side-chain
replacements in the MCAD protein may contribute to a better
understanding of the mechanisms underlying mutation-induced
protein misfolding and loss of enzyme function. MCAD is a
homotetrameric protein with each subunit consisting of three
structural domains, the N-terminal a-domain (aDN), the middle b-
domain (bD), and the C-terminal a-domain (aDC). Within the
family of fatty acid acyl-CoA dehydrogenases the MCAD enzyme
shows a comparatively broad spectrum of substrate utilization [18]
with the highest affinity for octanoyl-CoA, and contains a FAD
moiety as catalytic redox factor. Substrate and cofactor bind to
neighboring but structurally distinct grooves. Substrate binding is
confined to the individual subunits, whereas parts of the cofactor
molecules adopt an inter-subunit orientation.
In an attempt to classify novel mutations found in NBS we
established a comprehensive experimental setup which includes
circular dichroism (CD) spectroscopy, differential scanning fluo-
rimetry (DSF) monitoring 8-anilino-1-naphtalenesulfonic acid
(ANS) and flavin adenine dinucleotide (FAD) fluorescence, right
angle light scattering, and kinetics of thermal inactivation. This
allowed for detailed analysis of the conformation of wild-type and
variant MCAD proteins focusing on a domain-related view of
folding and mutation-induced unfolding events in the MCAD
protein. With fever being a distinctive clinical risk factor for
patients with MCADD, special emphasis was put on structural and
functional derangements related to thermal stress. Moreover, we
summarized and quantified the structural data and visualized the
molecular protein misfolding phenotype of the variant MCAD
proteins in a 3D plot comparing them to the wild-type, to
p.Lys329Glu, the classical severe mutation, and to p.Tyr67His,
discussed to be a mild mutation.
Materials and Methods
Mutations
In a previous study [16] we analyzed oligomerization, enzyme
kinetics, and overall stability of the MCAD wild-type protein and
10 variant MCAD proteins derived from ACADM missense
mutations identified in Bavarian NBS. In this study, we provide
detailed conformational analysis of wild-type and eight variant
MCAD proteins, p.Ala52Val, p.Tyr67His, p.Tyr158His,
p.Arg206Cys, p.Asp266Gly, p.Lys329Glu, p.Arg334Lys, and
p.Arg413Ser that were amenable to recombinant expression and
purification. Mutations were grouped according to the localization
of the respective amino acid side-chain replacement within the
three structural domains of the MCAD protein: i) N-terminal a-
domain (aDN), p.Ala52Val (c.155C.T), p.Tyr67His (c.199T.C),
ii) middle b-domain (bD), p.Tyr158His (c.472T.C), p.Arg206Cys
(c.616C.T), p.Asp266Gly (c.797A.G), and iii) C-terminal a-
domain (aDC), p.Arg334Lys (c.1001G.A), p.Arg413Ser
(c.1237C.A). A color code linked to the individual protein
domains (green, aDN; blue, bD; red, aDC) was used throughout.
Mutations are summarized in Table 1.
Nomenclature of Sequence Variations
GeneBank NM_000016.4 was used as cDNA reference
sequence. The recommendations of the Nomenclature Working
Group [19] were followed. Nucleotide +1 is the A of the ATG-
translation initiation codon. Amino acid numbering starts with the
translation initiator methionine as +1. Additionally, the traditional
nomenclature system of the MCAD protein is shown in a separate
column in Table 1. In this system, amino acid numbering starts at
codon 26 with the first 25 amino acids forming a mitochondrial
targeting peptide and being cleaved off to produce the mature
MCAD monomer [20].
Plasmid construction
The cDNA of the human ACADM gene (ACADM-encoding
pKK223 plasmid obtained as a gift from Jerry Vockley,
Pittsburgh, USA) was cloned into the prokaryotic expression
vector pMALc2X (NEB) encoding an N-terminal MBP (maltose-
binding protein) and a Factor Xa cleavage site. ACADM mutations
were constructed by use of the QuikChange Site-Directed
Mutagenesis Kit (Stratagene) and verified by DNA sequencing.
Transient expression of wild-type and variant MCAD in
COS-7 cells
COS-7 cells were maintained in RPMI 1640 medium with
stable glutamine supplemented with 10% fetal bovine serum and
1% antibiotics (PAA). For transient expression of wild-type and
variant MCAD proteins, wild-type and mutant ACADM cDNA
was subcloned in pEF-DEST51. After transfection of 2 million
cells with 2 mg DNA using the Amaxa electroporation system
(Lonza), cells were cultured for 48 h in basic medium. Culture
medium was changed every 24 h. Cells were harvested by scraping
and lysed by three freeze–thaw cycles in a lysis buffer (20 mM
Hepes pH 7.0, 200 mM NaCl containing 1% Triton X-100,
100 mg/ml digitonin and proteinase inhibitors), followed by
MCAD Protein Misfolding Phenotype
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20 min centrifugation at 14,000 rpm at 4uC. Supernatants were
kept at -80uC until being used for the activity assay.
MCAD enzyme activity assay
The MCAD enzyme activity was determined essentially as
described elsewhere [21] using a reaction medium with the
following composition: 200 mM Tris-HCL, 0.2 mM phenylpro-
pionyl-CoA, 1 mM ferrocenium hexafluorophosphate, pH 8.0.
Final protein concentration in the assay was 0.02 mg protein/ml.
Separation of substrate and product was performed by UHPLC-
UV.
Prokaryotic expression and purification
Expression and purification were essentially performed as
previously described [16]. In brief, the MCAD wild-type
pMALc2X expression plasmid was used to transform the E. coli
strain BL21-CodonPlus (Stratagene), whereas the E. coli strain
DH5a (Invitrogen) was co-transformed with expression plasmids
of variant human ACADM and pGroESL [22]. Bacteria transformed
with wild-type MCAD were grown in 2 l of dYT medium
supplemented with 100 mg/ml ampicillin, while variant proteins
were grown in the presence of 100 mg/ml ampicillin and 50 mg/
ml chloramphenicol. Protein overexpression was induced with
0.01 mM isopropylthio-b-D-galactoside (IPTG) at a post induc-
tion temperature of 28 uC for 20 hours. Recombinant proteins
were purified at 4 uC using ÄKTApurifier and ÄKTAprime
systems (GE Healthcare). After loading the crude extract on a
MBPTrap affinity chromatography column (GE Healthcare),
equilibrated with column buffer (20 mM Tris-HCl pH 7.4,
200 mM NaCl, 1 mM EDTA, 1 mM DTT), unbound proteins
were washed out and MBP fusion proteins were eluted with the
same buffer supplemented with 10 mM maltose, followed by size-
exclusion chromatography using a HiLoad 16/600 Superdex 200
column (GE Healthcare) equilibrated with size-exclusion buffer
(20 mM HEPES pH 7.0, 200 mM NaCl). The isolated tetrameric
fusion proteins were pooled and incubated with Factor Xa
(Novagen) for 12 hours at 4 uC to cleave off the MBP tag using a
protease to protein ratio of 1:20 (U mg) followed by final re-
chromatography (HiLoad 16/600 Superdex 200 column, GE
Healthcare) in size-exclusion buffer. The concentration of the
isolated tetrameric fraction was determined using the fluorescent
dye binding Quant-iT assay (Invitrogen). All purification steps of
wild-type MCAD are shown in Figure S1A and wild-type and
variant MCAD proteins were purified to homogeneity (Figure
S1B).
Circular dichroism spectroscopy
Far-UV CD spectra were recorded using a Jasco J-715
spectropolarimeter (Jasco, Gross-Umstadt, Germany) equipped
with a PTC 343 Peltier element. Experiments were performed in
quartz cuvettes with 0.1 cm path length at a protein concentration
of 0.15 mg/ml and far-UV spectra were recorded from 190 to
260 nm in 10 mM potassium phosphate, pH 8.0 at 20 uC. 16
spectra were accumulated for each protein analyzed and
subsequently baseline corrected. The composition of secondary
structure elements was calculated using the CD spectra deconvo-
lution software CDNN [23]. Thermal transition experiments were
monitored at 208 nm with a heating rate of 20 uC per hour. Data
were normalized by setting the signal of the native protein to 1.
ANS and FAD differential scanning fluorimetry
Fluorescence measurements with the wild-type and variant
MCAD enzymes (0.5 mg/ml) diluted in 20 mM HEPES buffer,
pH 7.0 and 200 mM NaCl were performed on a Cary Eclipse
fluorescence spectrophotometer equipped with a temperature-
controlled Peltier multicell holder (Varian). Intrinsic FAD
fluorescence and binding of the hydrophobic dye 8-anilino-1-
naphtalenesulfonic acid (ANS, Sigma-Aldrich) to surface exposed
hydrophobic groups was co-monitored (multiwavelength program)
during heat-induced denaturation experiments in the temperature
range from 25 uC to 65 uC at a heating rate of 1 uC/min. Changes
in ANS fluorescence emission were detected at 450 nm (excitation
at 395 nm, 5.0/10.0 nm slit widths), whereas intrinsic FAD
emission was monitored simultaneously at 530 nm (excitation at
450 nm, 5.0/10.0 nm slit widths). We ensured that no fluores-
cence resonance energy transfer occurred at the wavelengths used.
Transition midpoints (Tm1/2) were determined graphically with
Tm1/2 being the temperature at which half denaturation occurred.
Significances between wild-type and variant proteins were
calculated by one-way ANOVA followed by a Dunnett’s post test
(GraphPad Prism 5.0).
Right angle light scattering
Right angle light scattering (RALS) experiments were per-
formed on a Cary Eclipse fluorescence spectrophotometer
equipped with a temperature-controlled Peltier multicell holder
(Varian). Samples contained 0.08 mg/ml protein diluted in 20 mM
HEPES buffer, pH 7.0 and 200 mM NaCl. The increase in
turbidity was monitored in the temperature range from 25 uC to
65 uC at a heating rate of 1 uC/min (excitation at 330 nm,
Table 1. Mutations.
cDNA a Precursor protein (Trivial name) Mature protein c (Trivial name)
c.155C.T p.Ala52Val A52V p.Ala27Val A27V
c.199T.C p.Tyr67His Y67H p.Tyr42His Y42H
c.472T.C p.Tyr158His Y158H p.Tyr133His Y133H
c.616C.T p.Arg206Cys R206C p.Arg181Cys R181C
c.797A.G p.Asp266Gly D266G p.Asp241Gly D241G
c.985A.G p.Lys329Glu K329E p.Lys304Glu K304E
c.1001G.A p.Arg334Lys R334K p.Arg309Lys R309K
c.1237C.C p.Arg413Ser R413S p.Arg388Ser R388S
aReference sequence: GenBank accession no. M16827.1. Nucleotide numbering starts with A of the ATG initiation codon as +1.
cAfter cleavage of the 25 amino acid N-terminal mitochondrial targeting sequence.
doi:10.1371/journal.pone.0093852.t001
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emission 335 nm; 5.0 nm slit widths). Turbidity curves were
illustrated with GraphPad Prism 5.0.
Kinetics of thermal inactivation
Thermal inactivation experiments were performed using a
ferrocenium-based spectrophotometric assay [24]. MCAD protein
diluted in 100 mM HEPES, pH 7.6 supplemented with 0.1 mM
EDTA was incubated at five different temperatures in the range
from 32 uC to 44 uC for the indicated time intervals. MCAD
enzyme activity was subsequently measured by addition of 10 mM
octanoyl-CoA. Residual enzyme activities of n = 5 to n = 7
independent experiments were normalized to initial enzyme
activity prior to incubation (25 uC). The kinetic constants of
inactivation k were calculated by plotting the residual activity
against the measurement time.
Arrhenius plots result from plotting the logarithm of the five
kinetic constants against the respective inverse temperature.
Activation energy (EA) was determined from the slope of the
Arrhenius plot and is given as single value without measures of
variation.
3D plot of structural alterations in variant MCAD proteins
To visualize results from experiments investigating thermal
stability, kinetic stability, and conformation of MCAD wild-type
and variants, we combined data and developed relative scores
assessing the severity of mutation-induced changes. The parameter
thermal stability (y-axis) reflects the thermal unfolding behavior.
Values were based on the means of transition midpoints of thermal
denaturation as determined by CD spectroscopy, ANS-DSF or
FAD-DSF. The parameter kinetic stability (x-axis) represents the
activation energy (EA) as a measure of the threshold from the
active to the non-active protein upon application of thermal stress.
The parameter conformation (z-axis) arises from the results of CD
spectroscopy, ANS-fluorescence or intrinsic FAD-fluorescence
reflecting secondary structure, tertiary structure, and structural
integrity with no stress applied, i. e. at room temperature. A
numerical score was assigned to each of the experimental data
with values ranging from 9 (native state) to 1 (non-native state).
Results
Structural localization and functional impact of MCAD
side chain replacements
The mutations analyzed in this study affect side chains
distributed over the entire MCAD protein. Side chains Ala27
and Tyr133 of the mature peptide lacking the 25 amino acid signal
sequence are located at the core of the MCAD monomer, Lys304
and Arg309 are positioned at the subunit interface inside the
tetramer (Figure 1A), whereas all other side chains (Tyr42,
Arg181, Asp241, Arg388) are surface-exposed (Figure 1B and C).
Both substrate and cofactor are oriented towards the catalytic
core, however, they differentially interact with the MCAD protein
(Figure 1D). Only the acyl-moiety of the substrate is buried in the
substrate-binding cleft while the coenzyme-A moiety remains
solvent-exposed allowing for rapid exchange within catalytic
cycles. By contrast, the FAD cofactor is integral to the MCAD
3D structure and diffusion is impeded in the natively folded
tetrameric state.
Residual activity of all variant MCAD proteins expressed in
COS-7 cells was determined in order to analyze loss of function in
living cells. The variants p.Ala52Val, p.Tyr67His, and
p.Arg334Lys revealed high residual activity in the range from 45
to 91% as compared to the wild-type, whereas p.Arg206Cys,
p.Asp266Gly, and p.Arg413Ser showed activities between 21 and
34%. Only p.Tyr158His displayed low activity of 5%. When
compared to the specific enzyme activity of recombinantly
expressed and purified MCAD variants (Maier et al 2009),
p.Arg206Cys and p.Lys329Glu displayed a significant loss of
protein function in the eukaryotic environment. Note that
p.Arg413Ser is a kinetic variant with a substrate affinity reduced
by two orders of magnitude resulting in a catalytic efficiency
(Vmax/Km) of 1.7 compared to that of the wild-type of , 100.
Variant MCAD proteins show increased hydrophobicity
and decreased FAD binding capacity
First, we analyzed missense mutation-induced alterations of
variant MCAD conformations with respect to secondary structure,
hydrophobicity, and FAD binding in comparison to the wild-type.
The relative composition of secondary structure elements was
monitored by CD scans recorded in far-UV light between 190 and
260 nm. The CD spectra showed typical secondary structure
characteristics of proteins with predominating a-helical structures
and a lower amount of b-sheets represented by minima at 208 nm
and 222 nm, and a maximum at 193 nm, respectively (Figure 2A).
When compared to the wild-type, spectra of variant MCAD
proteins showed only slight differences. This was confirmed by
quantitative analysis of secondary structure elements by means of
CD spectra deconvolution (Table 2). For p.Tyr67His and
p.Lys329Glu, a decrease in the relative amount of a-helical
structures resulted in a higher share of b-strands. Although to a
lesser extent, the two other mutations mapping to aDC
(p.Arg334Lys, p.Arg413Ser) showed the same phenomenon,
whereas mutations in bD did not induce marked changes in the
secondary protein structure.
Global conformational changes were determined probing the
accessibility of a fluorescent dye (ANS) to hydrophobic groups
within the protein. The two variants mapping to aDN, p.Ala52Val
and p.Tyr67His, showed similar ground-state fluorescence at
ambient temperature as the wild-type (Figure 2B). By contrast, all
mutations affecting bD (p.Tyr158His, p.Arg206Cys, and p.As-
p266Gly) displayed elevated ground-state fluorescence indicating
partial unfolding at 25 uC. p.Tyr158His showed the most
pronounced changes with an increase by 15-fold, while the
ground-state fluorescence of p.Arg206Cys and p.Asp266Gly was
increased by 2- and 4-fold, respectively. Two of the three
mutations mapping to aDC, p.Lys329Glu and p.Arg413Ser,
produced a 2-fold elevation of the ground-state fluorescence,
whereas hydrophobicity of p.Arg334Lys was similar to that of the
wild-type.
Intrinsic fluorescence of the FAD cofactor allows for tracking
structural integrity of the MCAD protein as FAD is integral to the
natively folded tetrameric state. To investigate whether mutations
alter FAD binding capacity, we analyzed FAD fluorescence of
MCAD variants at 530 nm after 15 min incubation at room
temperature. Thermal denaturation assays demonstrated that
FAD is released from the protein in the course of the unfolding
process (Figure S2). All mutations induced elevated ground-state
FAD fluorescence signals as compared to wild-type MCAD
indicating partial loss of FAD binding capacity due to alteration
of the native state conformation (Figure 2C). The variant
p.Tyr158His showed the most pronounced alterations with an
increase in FAD fluorescence by 3-fold. Three mutations, each
mapping to one of the three protein domains, were associated with
an increase in intensity by 2-fold (p.Tyr67His, p.Arg206Cys,
p.Arg413Ser) while the impact of the remaining mutations
including p.Lys329Glu was less pronounced.
Taken together, all mutations with the exception of p.Ala52Val
showed conformational alterations with individual patterns of
MCAD Protein Misfolding Phenotype
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Figure 1. Localization of side chains affected by mutations and residual enzyme function of MCAD variants. (A) Mutations in the
ACADM gene map to side chains (red) of all regions of the MCAD monomer. The mature MCAD protein is shown and numbering of side chains refers
to the primary sequence after cleavage of an N-terminal 25 amino acids mitochondrial targeting peptide (see Table 1). Side chains, FAD cofactor
(yellow) and the substrate analogue 3-thiaoctanoyl-CoA (orange) are shown as stick models. (B, C) Structural localization of affected side-chains at the
surface of subunit A (gray) relative to the other subunits (B, green; C pink; D, blue) in the MCAD tetramer. (D) Surface view of the MCAD tetramer with
3-thiaoctanoyl-CoA (orange) bound to the substrate binding site and the positioning of FAD (yellow) relative to subunits A (gray), B (green), and D
(blue). (E) Relative enzyme activity of wild-type and variant MCAD proteins. Specific activity was determined using purified recombinant protein [16]
and residual activity was measured upon expression in COS-7 cells. Data are given as means and SD of three replicates.
doi:10.1371/journal.pone.0093852.g001
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Figure 2. Missense mutations induce conformational alter-
ations of variant MCAD proteins. (A) The composition of secondary
structure elements of wild-type and variant MCAD in the absence of
thermal stress was determined by circular dichroism applying the CD
spectra deconvolution software CDNN [23]. The spectra showed typical
secondary structure characteristics of proteins with predominating a-
helical content. (B) Hydrophobicity of wild-type and variant MCAD
proteins in the absence of thermal stress was determined using the
fluorescent dye ANS. An increase in the fluorescence signal points to
increased binding of the ANS dye to hydrophobic groups. Data
represent means and SEM of three independent experiments. (C)
Structural integrity of wild-type and variant MCAD proteins in the
absence of thermal stress was determined by intrinsic FAD fluores-
cence. An increase in the fluorescence signal points to a release of FAD
from the MCAD protein. Data represent means and SEM of three
independent experiments. (B, C) Data are grouped according to the
domain affected by mutations (aDN, N-terminal a-helical domain; bD, b-
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derangement as to different structural aspects. p.Tyr67His and
p.Lys329Glu had a particular impact on the secondary protein
structure, partial unfolding probing global hydrophobicity was
most pronounced for mutations mapping to bD, and variants of all
domains showed disturbed FAD binding.
Mutations mapping to bD are associated with
accelerated heat-induced unfolding
Among protein misfolding diseases with a loss-of-function
molecular phenotype, the MCADD clinical phenotype has proven
to be particularly vulnerable to fever [15,25,26]. In order to get
structural insight into this disease mechanism, we investigated
heat-induced unfolding of variant MCAD proteins by means of
CD-spectroscopy, as well as ANS-DSF and FAD-DSF. We
monitored denaturation of a-helical secondary structures by
means of CD at 208 nm in order to determine transition
midpoints between folded and unfolded states (Tm1/2) (Figure 3A,
Table 3). In comparison to wild-type MCAD (Tm1/2 56.5 uC),
p.Tyr158His was by far the most instable variant with a marked
shift of the curve to lower temperatures and a Tm1/2 deviation of
12 uC (Tm1/2 44.5 uC). p.Arg206Cys also displayed markedly
reduced stability with a decrease in Tm1/2 by 6.5 uC. All other
variants exhibited a reduced stability of the secondary structure,
though to a lesser degree with Tm1/2-deviations of 2.5 to 4 uC. In
this group, p.Arg413Ser and p.Ala52Val showed the most
pronounced shift (Tm1/2 52.0 uC), the variants p.Tyr67His,
p.Arg334Lys, and p.Asp266Gly were in the medium range,
whereas p.Lys329Glu was the most stable variant (Tm1/2 54.0 uC).
To analyze heat-induced loss of native-state conformation, we
monitored FAD fluorescence emission at increasing temperatures.
The MCAD wild-type protein showed a Tm1/2 of 58.3 uC
denoting the midpoint of transition from the native cofactor-
bound state to the unfolded state with complete cofactor release
(Table 3, Figure S2). None of the variants showed marked changes
in the shape of the denaturation curves. However, most curves
were shifted to lower temperatures indicating early FAD release
upon thermal stress (Figure 3B). Surprisingly, the variant
p.Lys329Glu was associated with a shift of the FAD fluorescence
curve to higher release temperatures (Tm1/2 59.0 uC). For
p.Arg334Lys we observed a curve virtually mapping to that of
wild-type MCAD and p.Asp266Gly, p.Arg413Ser, and p.Tyr67-
His displayed only moderately left-shifted curves. Three variants
(p.Ala52Val, p.Arg206Cys, p.Tyr158His) mapping to aDN and
bD were associated with structural rearrangements at the FAD
binding site leading to FAD release at lower temperatures. Again,
the variant p.Tyr158His showed the most pronounced alteration
with a DTm1/2 of 12 uC (Table 3) correlating well with the shift in
Tm1/2 observed in CD-spectroscopy experiments. Interestingly,
the amino acid residue affected by this mutation is an essential part
of the active site directly interacting with the FAD cofactor [27].
ANS-DSF is an excellent means to monitor global thermal
unfolding events [16,28–30] and transition midpoints for muta-
tions analyzed in this study have been determined before [16].
However, application of varying scan rates as a function of
temperature in our previous work did not allow for fine-mapping
of unfolding profiles. To enable this, we performed ANS-DSF
experiments at a fixed scan rate of 1 uC/min. Under these
conditions, the values for Tm1/2 were well comparable to those
obtained by CD-spectroscopy (Table 3). Analysis of the pattern of
thermal denaturation curves revealed a subtle biphasic transition
with a different slope in the low temperature range between 45 uC
and 53 uC for the wild-type (Tm1/2 56.2 uC) (Figure 3C). Biphasic
unfolding transitions have previously been reported for the MCAD
protein [14] and other disease-related multi-domain proteins and
different transition phases were associated with unfolding of
distinct structural domains [31–33].
Variants with an amino acid side-chain substitution in aDN
displayed straight curves with a minor shift to lower temperatures
indicating moderately decreased stability of the enzyme equally
affecting the conformation of all domains. Unfolding patterns of
bD variants were severely altered. The p.Tyr158His variant
revealed a marked shift in transition and a steeper slope than all
other mutations, reflecting the most pronounced destabilization of
the protein (Tm1/2 44.9 uC). Accordingly, Tm1/2 was changed to a
similar extent as observed by the above methods. p.Arg206Cys
and p.Asp266Gly disclosed a marked biphasic transition with a
left-shift of the whole curve and an even more pronounced shift of
the low-temperature transition. Thus, mutations mapping to bD
particularly affected the low-temperature unfolding transition.
These observations may indicate that unfolding of bD correlates
with the low-temperature transition. Mutations mapping to aDc,
in particular p.Lys329Glu and p.Arg334Lys, showed unfolding
curves very similar to that of the wild-type protein indicating good
thermal stability. The p.Arg413Ser variant displayed a reduced
mean unfolding transition (Tm1/2 51.9 uC) and a clear shift of the
low-temperature transition but this was less pronounced than for
variants p.Arg206Cys and p.Asp266Gly that also showed biphasic
transitions.
In conclusion, considering the localization of side chain
replacements in different domains, mutations mapping to bD
displayed the most pronounced alterations affecting all parameters
tested. In addition to bD variants, p.Ala52Val of aDN was
associated with early loss of FAD binding and the aDC variant
p.Arg413Ser displayed a marked left-shift of the low-temperature
range unfolding transition.
MCAD variants are prone to aggregation
To investigate whether thermal stress leads to accelerated
protein aggregation of MCAD variants we carried out RALS
experiments probing the formation of insoluble aggregates. Based
on hydrophobic self-association of the purified proteins, the
intensity of the scattered light at 335 nm was detected in right
angle to the excitation light of 330 nm and plotted as a function of
temperature applied to the sample (Figure 4). Mutations mapping
to aDN induced a slight shift of the onset of aggregation to lower
temperatures resulting in curves indicative for a similar aggrega-
tion behavior as the wild-type protein. Also in this set of
experiments MCAD variants of bD displayed the most distinct
alterations. Aggregation curves for all three variants (p.Tyr158His,
p.Arg206Cys, p.Asp266Gly) were markedly shifted indicating an
earlier onset of aggregation than observed for the wild-type and all
other variants analyzed here. For p.Tyr158His we observed the
most pronounced left-shift with the steepest slope. The pattern of
aggregation for mutations mapping to aDC was moderately left-
shifted and comparable to that observed in aDN.
In summary, missense mutations in the ACADM gene mapping
to aDN or aDC only showed minor acceleration in the formation
of insoluble aggregates upon thermal stress, whereas variants of
bD were distinctly aggregation prone and induced aggregation
already at lower temperatures.
Kinetics of thermal inactivation
Following the analysis of the impact of increasing temperatures
on protein structure we investigated loss of MCAD enzyme
function upon thermal stress. Thermal inactivation of recombinant
MCAD wild-type and variants was determined over time at
temperatures between 32 uC and 44 uC (Figure 5A). Velocity
constants (k) were calculated from the resulting thermal inactivation
MCAD Protein Misfolding Phenotype
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Figure 3. Mutations of the middle b-domain of the MCAD protein are associated with accelerated heat-induced unfolding. (A)
Thermal stress-induced denaturation monitored by circular dichroism (CD) probing loss of secondary structure. Denaturation profiles of the fractional
change of the a-helical secondary structures of wild-type and variant MCAD were measured at 208 nm. Data are given as non-linear fit of the mean of
three independent experiments where 1 represents the native state and 0 the unfolded state. (B) Thermal stress-induced denaturation monitored by
FAD differential scanning fluorimetry (DSF) probing FAD binding capacity. The temperature dependent release of intrinsic FAD of wild-type and
variant MCAD was measured at 530 nm (excitation 450 nm). Data are given as non-linear fit of the mean of three independent experiments where 0
represents the native state and 1 the unfolded state. (C) Thermal stress-induced denaturation monitored by ANS-DSF probing global unfolding.
Unfolding profiles of wild-type and variant MCAD were determined as changes in ANS fluorescence emission at 450 nm (excitation 395 nm). All
unfolding patterns revealed a biphasic unfolding mechanism with a distinct low- and high-temperature transition, depicted in two red lines in the
unfolding curve of wild-type MCAD. Data are grouped according to the domain affected by mutations (aDN, N-terminal a-helical domain; bD, b-sheet
domain; aDC, C-terminal a-helical domain) and given as mean of three independent experiments where 0 represents the native state and 1 the
unfolded state.
doi:10.1371/journal.pone.0093852.g003
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profiles and plots of the logarithm of the kinetic constants (lnk)
against the inverse temperature revealed a linear Arrhenius
relationship (Figure 5B). Differences in the slope of Arrhenius plots
reflect distinct activation energies (EA) for conversion of MCAD
variants from an active conformational state into an inactivated and
potentially non-native state (Figure 5C). p.Ala52Val and p.Tyr67-
His of aDN as well as p.Arg334Lys of aDC showed EA at wild-type
level. All other variants mapping to bD and aDC displayed reduced
kinetic stability. The lowest EA of all variants was observed for
p.Tyr158His.
In summary, kinetics of thermal inactivation allowed to gain
insight into unfolding dynamics at the active center of the MCAD
protein. Variants located in aDN were completely unaffected,
possibly due to the remote position to the active site. Mutations
mapping to bD and aDC induced decreased kinetic stability as to
both global and local unfolding processes. Notably, a side chain
replacement remote to the active site structure, p.Arg334Lys, did
not alter dynamics of heat-induced unfolding.
Structural and conformational consequences of
mutations in the ACADM gene
To provide an integrated view of the structural consequences of
ACADM mutations we classified MCAD variants based on
conformation, kinetic stability, and thermal stability and visualized
the results as a 3D plot (Figure 6).
All mutations analyzed here induced reduced thermal stability
when compared to the wild-type. The deleterious structural effects
of the p.Tyr158His missense mutation demonstrated by the several
experimental approaches applied in this study resulted in opposite
positioning of this variant to wild-type in the 3D plot. The other
two variants located in the bD, namely p.Arg206Cys and
p.Asp266Gly, together with p.Lys329Glu and p.Arg413Ser of
aDC, built a cluster of relative instability with respect to native-
state conformation and thermodynamic stability. The variants
p.Ala52Val and p.Arg334Lys were assigned an intermediate
position between p.Tyr67His and wild-type with respect to
native-state conformation. p.Ala52Val showed a slightly reduced
thermal stability and both variants presented with equal or higher
thermal stability as compared to p.Tyr67His. Thus, p.Lys329Glu,
the classical severe mutation, and p.Tyr67His, discussed to be a
particularly mild mutation, did not constitute the edges of the plot.
To summarize, mutations mapping to bD showed the most
severe structural alterations with some of the variants displaying
more unfavorable structural properties than p.Lys329Glu and
others being even less affected than p.Tyr67His.
Table 3. Mean transition midpoints of thermal denaturation (CD spectroscopy, FAD fluorescence, ANS fluorescence).
CD a ANS-DSF b FAD-DSF c
Tm1/2 (6C) Tm1/2 (6C) SEM Tm1/2 (6C) SEM
WT 56.5 56.4 0.53 58.3 0.53
p.Ala52Val 52.0 52.2 0.37 54.2 0.37
p.Tyr67His 52.5 52.2 0.32 55.7 0.32
p.Tyr158His 44.5 44.9 0.43 46.3 0.43
p.Arg206Cys 50.0 49.1 0.30 52.2 0.30
p.Asp266Gly 53.5 51.4 0.70 56.4 0.70
p.Lys329Glu 54.0 55.1 0.29 59.0 0.29
p.Arg334Lys 53.5 55.5 0.33 57.4 0.33
p.Arg413Ser 52.0 52.1 0.52 56.1 0.52
aThree denaturation profiles were combined to calculate one value for Tm1/2.
b,cAssayed in triplicates, data are given as means and SEM.
doi:10.1371/journal.pone.0093852.t003
Figure 4. MCAD variants are prone to aggregation. Right angle light scattering experiments probing thermal stress-induced aggregation. The
intensity of the scattered light as a function of increasing temperature was determined at 335 nm (excitation 330 nm) for variants arising from
mutations mapping to the N-terminal a-domain (aDN), variants arising from mutations mapping to the middle b-domain (bD), and variants with
amino acid substitutions in the C-terminal a-domain (aDC).
doi:10.1371/journal.pone.0093852.g004
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Discussion
The introduction of expanded NBS programs including early
detection of MCADD raised uncertainties about the clinical
relevance of novel ACADM mutations identified in individuals
showing biochemical abnormalities in the first days of life. Before
the screening era p.Lys329Glu was by far the most prevalent
mutation, preferentially identified in symptomatic patients pre-
senting with a metabolic crisis [34,35]. Later, p.Tyr67His was
identified as the second most prevalent mutation. To date, it has
only been detected in babies identified by NBS and there are no
reports of patients presenting clinically with this mutation
[7,11,15]. On the basis of MCAD enzyme activity determinations,
one study came to the conclusion that this variant is of no clinical
relevance [36]. The assessment of pathogenicity of mutations
identified after positive NBS is of major clinical relevance since the
disclosure of a genetic disease is associated with a high burden for
the patients and their families [37,38]. However, data describing
the consequences of these mutations at the molecular level and the
availability of experimental tools for this assessment, are scarce. At
the clinical level, the natural course of the disease in individuals
carrying these novel mutations is unlikely to be unraveled as
detected asymptomatic babies are protected from metabolic
decompensation by the implementation of emergency protocols.
At the biochemical level, markers such as blood acylcarnitine
concentrations do not correlate well with the risk of metabolic
decompensation [39,40]. A recent study established risk stratifica-
tion based on residual MCAD enzyme activity obtained from
patient blood cells and showed that an enzyme activity of less than
1% is associated with an increased risk of fatal neonatal
presentation and enzyme activities below 10% enhance the risk
of hypoglycemia [41]. However, reported enzyme activities linked
to single mutations vary over a wide range and can differ
Figure 5. Kinetics of thermal inactivation. (A) Kinetics of thermal inactivation experiments probing dynamics of heat-induced loss of function.
Wild-type and variant MCAD proteins were incubated at indicated temperatures and residual activity was plotted as a function of incubation time. (B)
Arrhenius Plots resulting from kinetic constants k of time-dependent thermal denaturation experiments. (C) Activation energies (EA) calculated from
Arrhenius Plots reflect the energy barrier between the conformational state with full residual activity and the non-active state after application of
thermal stress.
doi:10.1371/journal.pone.0093852.g005
Figure 6. Molecular phenotypes of thermal, kinetic, and
conformational stability. Data derived from experiments depicted
in Figures 2, 3, and 5 were combined and visualized as 3D plot. Thermal
stability (y-axis) refers to midpoints of thermal denaturation determined
by CD spectroscopy, FAD-DSF, and ANS-DSF. Kinetic stability (x-axis)
refers to the EA determined by thermal inactivation experiments.
Conformational stability (z-axis) refers to secondary structure (CD
spectra), hydrophobicity (ANS fluorescence), and FAD binding capacity
(intrinsic FAD fluorescence) in the absence of heat-induced stress.
doi:10.1371/journal.pone.0093852.g006
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substantially when residual enzyme activity is analyzed in patient
cells or after overexpression of variant proteins [7,16,36,42,43].
Furthermore, in all cohorts evaluating the pathogenicity of
ACADM genotypes [11,36,42] mutations identified in NBS cohorts
are mostly observed in compound heterozygosity with p.Lys329-
Glu or p.Tyr67His. Only few MCAD variants (5% in [41] and
20% in [11]) were found in other combinations, and even less in
the homozygous state.
Prediction tools or 3D-structural analyses are often used to
estimate the pathogenic impact of ACADM mutations. However,
this approach often is not straight-forward and may lead to
misassumptions. Based on visual analysis of side-chain replace-
ments in the MCAD 3D structure, one would judge mutations
p.Tyr67His, p.Arg206Cys, p.Asp266Gly, and p.Arg413Ser, all
affecting protein surface regions, as not damaging. In the case of
p.Arg413Ser (mapping to Arg388 in the mature protein) the
interaction with the substrate, however, would suggest a loss-of-
function phenotype. At the experimental level, we showed that
p.Arg413Ser, p.Asp266Gly (Asp241), and p.Arg206Cys (Arg181)
displayed a severe structural phenotype, whereas only Tyr67His
(Tyr42) showed a mild structural phenotype in accordance with
the mild clinical phenotype associated to this mutation. The
PolyPhen-2 polymorphism phenotyping tool (www.genetics.bwh.
harvard.edu/pph2/) predicts the possible impact of an amino acid
substitution on structure and function of a human protein. A query
for p.Tyr67His resulted in a score of 0.077 and the side chain
replacement was classified as benign. Mutations p.Arg206Cys and
p.Arg413Ser were scored 0.999 and classified as probably
damaging. However, a score of 0.000 for p.Asp266Gly suggested
a benign structural phenotype. This in silico prediction did not
match our observation of a severe structural phenotype for
p.Asp266Gly resembling that of p.Arg206Cys and p.Arg413Ser.
Thus, elucidating the molecular consequences of mutations on
variant proteins in model systems, which generate data specific to
individual MCAD variants, is considered to be a useful tool to gain
insight into their pathogenicity.
We previously provided first evidence that ACADM mutations
identified in newborn screening induce considerable structural
alterations [16]. In the work presented here we significantly
expanded the experimental program focusing on the effect of
thermal stress on conformational integrity as well as on enzymatic
function. In a domain-related view, we tracked mutation-induced
structural derangements with respect to aDN, bD, and aDC. A 3D
plot summarizing and quantifying the structural phenotype of the
variants in comparison to the wild-type on one hand and to the
two benchmark mutations p.Tyr67His and p.Lys329Glu on the
other, allowed for visualization of the severity of conformational
derangement induced by ACADM mutations identified by new-
born screening. Notably, the mild p.Tyr67His and the severe
p.Lys329Glu did not constitute the phenotypic extremes of the
panel of mutations analyzed. The classification applied here rather
resulted in two groups of variant MCAD proteins. The group
associated with mild structural deteriorations comprised the wild-
type protein and p.Tyr67His as well as p.Ala52Val and
p.Arg334Lys. The other group presenting moderate to severe
structural deteriorations comprised p.Lys329Glu as well as
p.Arg206Cys, p.Asp266Gly, p.Arg413Ser and at the extreme,
p.Tyr158His. Interestingly, mutations identified in NBS either
induced structural alterations that were less severe than those
observed for p.Tyr67His or more severe than those seen in the
presence of p.Lys329Glu. Moreover, mutations p.Tyr67His and
p.Lys329Glu displayed similar behavior with respect to various
parameters of protein conformation and stability. For both
variants only moderate changes were observed with respect to
conformation and thermal unfolding or aggregation. Furthermore,
both variants displayed a similar shift in the relative distribution of
secondary structure elements towards b-strands and b-turns.
However, p.Tyr67His and p.Lys329Glu were clearly separated
by kinetic stability. This parameter was the best discriminator for
both groups. By contrast, thermal stability as determined by DSF
assays did not discriminate these two groups.
Based on the data from the present study, all mutations
mapping to bD can be categorized as prone to misfolding,
unfolding, and functional inactivation. In addition, two out of
three mutations affecting residues in aDC can be assigned to the
group of severely affected variant MCAD proteins. Variants
arising from mutations located in bD displayed more severe
structural alterations in all aspects as compared to p.Lys329Glu
located in aDC. The mutation p.Tyr158His mapping to the core
of the MCAD monomer induced the most profound alterations.
Mutations p.Arg206Cys, p.Asp266Gly, and p.Arg413Ser showed
molecular phenotypes comparable to those induced by p.Lys329-
Glu and may therefore be classified as just as severe. The latter
group of mutations displayed substantial reduction in residual
enzyme activity when compared to the respective specific activity,
a fact that may underscore the impact of structural derangement
on protein function in vivo. In the mild group, p.Ala52Val induced
alterations comparable to p.Tyr67His and the structural pheno-
type of p.Arg334Lys was almost unaffected. It seems tempting to
assume that the mutations assigned to the mild group or mutations
mapping to aDN in general bear a lower risk of metabolic
decompensation. Nevertheless, eight mutations mapping to this
domain (c.145C.G, Q24E; c.157C.T, R28C; c.233T.C,
p.I78T; c.250C.T, p.L84F; c.253G.T, p.Gly85Cys; c.320T.C,
p.Leu107Ser; c.346T.G, p.Cys116Gly; c.443G.A, p.Arg148Lys)
have previously been associated with intermediate to severe clinical
phenotypes including sudden death [7,11,44]. Moreover, the mild
structural effects determined for p.Ala52Val (Ala27 in the mature
protein) are in apparent conflict with the loss in enzymatic function
observed. The side chain 27 is not in close proximity to the active
site but Ala27 maps to the conjunction of two a-helices and its
replacement by valine is likely to displace the far N-termini that
exhibit mutual side chain interactions between subunits across the
dimer interface. In line with our observation that p.Ala52Val
displayed the third lowest melting point of FAD-DSF, proper
positioning of N-termini may be of fundamental importance for
MCAD structural integrity and consequently for MCAD function.
Notably, the classification of the two groups with respect to kinetic
stability, i. e. thermal stress-induced loss of enzymatic function,
correlated with residual activity determined in eukaryotic cells.
Residual enzyme activity ranged from 45% to 91% in the mildly
affected group and from 5% to 34% in the group of severely affected
MCAD variants.
In conclusion, classification of mutations constituting the mild
group either as pathogenic or as clinically non-relevant that would
exclude patients from clinical follow-up and emergency proce-
dures is still challenging. However, data derived from structural
and functional analyses of variant MCAD proteins support the
notion that mutations identified in NBS induce significant
alterations and may thus be of clinical relevance. In particular,
mutations constituting the severe group, p.Tyr158His, p.Arg206Cys,
p.Asp266Gly, and p.Arg413Ser may be associated with a significant
clinical risk comparable to that associated with the classic ACADM
mutation p.Lys329Glu. In the absence of adequate biochemical or
clinical criteria, the degree of conformational alterations could be a
valuable tool to estimate the risk of metabolic decompensation. This
may hold particularly true, when data from protein structure analysis
are considered in conjunction with functional parameters. On the
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structural level, the molecular phenotype resulting from ACADM
mutations identified in NBS presented here depends on the intra-
molecular site of structural alterations with the central b-domain
being particularly prone to conformational derangement and
destabilization. On the functional level it is of critical importance
whether and to what extent thermal stress affects the function of the
MCAD enzyme.
The clinical observation of metabolic decompensation being
considerably aggravated with fever has led to the assumption that
the patient’s temperature has impact on the molecular phenotype
[4,7,10,14,39,41,45]. We showed here that mutations in the
ACADM gene lower the temperature threshold at which MCAD
loss-of-function occurs. Consequently, increased temperature as it
happens during intercurrent infections, significantly enhances the
risk of further conformational derangement and loss of function of
the MCAD enzyme explaining the life-threatening clinical courses
observed during fever episodes in patients suffering from
MCADD. Two possible strategies may help to address this issue.
First, at short notice, the necessity of early and aggressive
antipyretic treatment to avoid further loss in MCAD enzyme
activity should be emphasized towards caregivers. Secondly, in the
medium term, the development of pharmacological chaperones
that bind to the variant MCAD protein and induce its
conformational stabilization and functional rescue would provide
a specific treatment strategy protecting MCADD patients from
metabolic decompensation, morbidity, and early death. This view
is strongly supported by positive experiences with two approved
drugs acting as pharmacological chaperones in genetic diseases,
sapropterin dihydrochloride for phenylketonuria [46,47] and
tafamidis for familial amyloid polyneuropathy [48].
Supporting Information
Figure S1 Purification of MCAD wild-type and variant
proteins. (A) Complete representation of all purification steps of
wild-type MCAD expressed in E. coli BL21-CodonPlus. Lane 1,
not transformed BL21-CodonPlus cells as negative control. Lane
2, crude extract of lysed BL21-CodonPlus transformed with
MCAD pMAL-c2X. Lane 3, pooled fraction after affinity
chromatography and size-exclusion chromatography showing
high yield of MBP-MCAD fusion protein and a minor share of
MBP protein. Lane 4, equal amounts of MBP protein and MCAD
protein after cleavage by factor Xa. Lane 5, pooled tetrameric
fraction after re-chromatography by size-exclusion chromatogra-
phy. (B) Pooled tetrameric fraction of wild-type and variant
MCAD proteins after factor Xa cleavage and re-chromatography.
(TIFF)
Figure S2 Intrinsic fluorescence of cofactor FAD allows
for determination of structural integrity of the MCAD
protein. (A) FAD fluorescence scans of the saturated and not
saturated MCAD wild-type before (native) and after (denatured)
thermal denaturation in comparison to the fluorescence of an FAD
standard with the same subunit concentration as the protein
sample. (B) Thermal denaturation curves of temperature depen-
dent intrinsic FAD release from MCAD wild-type due to partial or
complete unfolding of the enzyme monitored at 530 nm
(excitation 450 nm) compared to the fluorescence changes of an
FAD standard with the same subunit concentration.
(TIFF)
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9. Maier EM, Liebl B, Röschinger W, Nennstiel-Ratzel U, Fingerhut R, et al.
(2005) Population spectrum of ACADM genotypes correlated to biochemical
phenotypes in newborn screening for medium-chain acyl-CoA dehydrogenase
deficiency. Hum Mut 25: 443–452.
10. Nichols MJ, Saavedra-Matiz CA, Pass KA, Caggana M (2008) Novel mutations
causing medium chain acyl-CoA dehydrogenase deficiency: under-representa-
tion of the common c.985 A . G mutation in the New York state population.
J Med Genet 146A: 610–619.
11. Smith EH, Thomas C, McHugh D, Gavrilov D, Raymond K, et al. (2010)
Allelic diversity in MCAD deficiency: the biochemical classification of 54
variants identified during 5 years of ACADM sequencing. Mol Genet Metab
100: 241–250.
12. Zschocke J, Schulze A, Lindner M, Fiesel S, Olgemöller K, et al. (2001)
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32. Jakob U, Meyer I, Bügl H, André S, Bardwell JC, et al. (1995) Structural
organization of procaryotic and eucaryotic Hsp90. Influence of divalent cations
on structure and function. J Biol Chem 270: 14412–14419.
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